腱鞘巨细胞瘤的发病机制研究进展

doi:10.19438/j.cjoms.2026.02.015

中国口腔颌面外科杂志 ›› 2026, Vol. 24 ›› Issue (2): 190-195.doi: 10.19438/j.cjoms.2026.02.015

腱鞘巨细胞瘤的发病机制研究进展

沈佳宸, 严思其, 李烨, 杨驰^*, 郑吉驷^*

上海交通大学医学院附属第九人民医院口腔外科,上海交通大学口腔医学院,国家口腔医学中心, 国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所, 中国医学科学院口腔颌面再生医学创新单元,上海 200011

收稿日期:2025-05-12 修回日期:2025-07-02 出版日期:2026-03-20 发布日期:2026-04-02
通讯作者: 郑吉驷,E-mail：zhengjisi88@gmail.com;杨驰,E-mail：yangchi63@163.com。^*共同通信作者
作者简介:沈佳宸（2004—）,女,本科,E-mail：jessie2004@sjtu.edu.cn

Research progress in the pathogenesis of tenosynovial giant cell tumor

Shen Jiachen, Yan Siqi, Li Ye, Yang Chi, Zheng Jisi

Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology; Shanghai Research Institute of Stomatology; Research Unit of Oral and Maxillofacial Regenerative Medicine, Chinese Academy of Medical Sciences. Shanghai 200011, China

Received:2025-05-12 Revised:2025-07-02 Online:2026-03-20 Published:2026-04-02

摘要/Abstract

摘要： 腱鞘巨细胞瘤（tenosynovial giant cell tumor,TGCT）属于良性间充质肿瘤,起源于关节滑膜和肌腱鞘,可发生于全身所有关节,根据生长方式不同分为局限型和弥漫型。目前对于TGCT的发生机制尚不明确,早期认为其为炎症性疾病,但因其细胞遗传学上的克隆性异常、肿瘤自主性生长和某些基因的特异性高表达,现阶段主流观点认为TGCT是一种肿瘤性病变。本文从多个角度,包括TGCT基因层面改变、分子层面多种细胞因子的变化和细胞层面多种细胞间的相互作用,对TGCT的最新研究进展作一综述,探讨导致肿瘤发生和发展的机制,旨在为该肿瘤的基础研究和临床诊治提供参考。

关键词: 腱鞘巨细胞瘤, 发病机制, 基因突变, 细胞因子, 细胞间互作

Abstract: Tenosynovial giant cell tumor(TGCT) is a benign mesenchymal tumor originated from the synovium of joints and tendon sheaths, which might occur in any joint of the body. It is classified into localized and diffused types based on its different growth patterns. The exact pathogenesis of TGCT remains unclear presently. While it was initially thought to be an inflammatory condition, the majority now perceives TGCT to be a neoplastic lesion due to its genetically clonal abnormalities, the autonomous growth of tumors and the highly specific expression of certain genes. This review summarized the latest advancements in genetic alterations, molecular changes in various cytokines and cellular interactions of TGCT, and explored the mechanisms that lead to the formation and progression of tumor, aiming to provide references for basic research, clinical diagnosis and treatment.

Key words: Tenosynovial giant cell tumor, Pathogenesis, Gene mutation, Cytokines, Intercellular Interactions

中图分类号:

R739.8

沈佳宸, 严思其, 李烨, 杨驰, 郑吉驷. 腱鞘巨细胞瘤的发病机制研究进展[J]. 中国口腔颌面外科杂志, 2026, 24(2): 190-195.

Shen Jiachen, Yan Siqi, Li Ye, Yang Chi, Zheng Jisi. Research progress in the pathogenesis of tenosynovial giant cell tumor[J]. China J Oral Maxillofac Surg, 2026, 24(2): 190-195.

参考文献

[1] Stacchiotti S, Dürr HR, Schaefer IM, et al.Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts[J]. Cancer Treat Rev, 2023, 112: 102491.
[2] Huang WP, Gao G, Yang Q, et al.Malignant giant cell tumors of the tendon sheath of the right hip: a case report[J]. World J Clin Cases, 2022, 10(29): 10763-10771.
[3] 杨肖, 张茜, 耿宁, 等.右侧颞下颌关节弥漫性腱鞘巨细胞瘤伴软骨样化生1例[J]. 华西口腔医学杂志, 2017, 35(2): 223-226.
Yang X, Zhang Q, Geng N, et al.The diffuse giant cell tumor of tendon sheath with chondroid metaplasia in right temporomandibular joint: a case report[J]. West China Journal of Stomatology, 2017, 35(2): 223-226.
[4] Córdoba-Fernández A, Sánchez-Robles LJ, Lobo-Martín A. Tenosynovial giant cell tumor in the forefoot: two case reports and literature review[J]. J Am Podiatr Med Assoc, 2021, 111(3): Article_25.
[5] Robert M, Farese H, Miossec P.Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features[J]. Front Immunol, 2022, 13:820046.
[6] Dania V, Stavropoulos NA, Gavriil P, et al.Treatment modalities for refractory-recurrent tenosynovial giant cell tumor(TGCT): an update[J]. Medicina (Kaunas), 2024, 60(10): 1675.
[7] Wytiaz V, Siegel G, Chugh R.Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT)[J]. Expert Rev Anticancer Ther, 2024, 24(12): 1229-1236.
[8] Awosusi BL, Attia OM.Recurrent localized tenosynovial giant cell tumor of the left ring finger: a case report and literature review[J]. Cureus, 2024, 16(3): e55962.
[9] Yotsuya K, Shido Y, Matsuyama Y.Invasion patterns and long-term clinical outcomes of diffuse tenosynovial giant cell tumor of the ankle joint[J]. Cureus, 2024, 16(3):e56148.
[10] Kolisetty PV, Ali SS, Ahmad I, et al.Giant cell tumor of the tendon sheath of the hand: analysis of factors impacting recurrence[J]. Indian J Plast Surg, 2024, 57(2): 123-128.
[11] 丁若仪,何冬梅. 累及颞下颌关节和颅底的肿瘤与类肿瘤病变诊治进展[J]. 中国实用口腔科杂志,2021, 14(4):493-498.
Ding RY, He DM.Advances in the diagnosis and treatment of tumors and tumor-like diseases in the temporomandibular joint and skull base[J]. Chinese Journal of Practical Stomatology, 2021, 14(4): 493-498.
[12] Gelderblom H, Bhadri V, Stacchiotti S, et al.Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2024, 403(10445):2709-2719.
[13] Kemp AK, Brigman B, Siegel G, et al.Tenosynovial giant cell tumor and pigmented villonodular synovitis[J]. J Am Acad Orthop Surg, 2025, 33(11): e593-e602.
[14] Palmerini E, Trent JC, Hornicek FJ Jr.Medical management of tenosynovial giant cell tumor[J]. Curr Oncol Rep, 2025, 27(7): 844-855.
[15] Stern S, McKenzie PF, Bernthal N, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry[J]. Future Oncol, 2025, 21(12): 1501-1510.
[16] West RB, Rubin BP, Miller MA, et al.A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells[J]. Proc Natl Acad Sci U S A, 2006, 103(3): 690-695.
[17] Kager M, Kager R, Falek P, et al.Tenosynovial giant cell tumor[J]. Folia Med Cracov, 2022, 62(2): 93-107.
[18] Fletcher JA, Henkle C, Atkins L, et al.Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: confirmation of trisomy 7 in uncultured cells[J]. Genes Chromosomes Cancer, 1992, 4(3): 264-266.
[19] Layfield LJ, Meloni-Ehrig A, Liu K, et al.Malignant giant cell tumor of synovium (malignant pigmented villonodular synovitis)[J]. Arch Pathol Lab Med, 2000, 124(11): 1636-1641.
[20] Sciot R, Rosai J, Dal Cin P, et al.Analysis of 35 cases of localized and diffuse tenosynovial giant cell tumor: a report from the Chromosomes and Morphology (CHAMP) study group[J]. Mod Pathol, 1999, 12(6): 576-579.
[21] Nakayama S, Nishio J, Nakatani K, et al.Giant cell tumor of tendon sheath with a t(1;1)(p13;p34) chromosomal translocation[J]. Anticancer Res, 2020, 40(8): 4373-4377.
[22] Nishio J, Kamachi Y, Iwasaki H, et al.Diffuse-type tenosynovial giant cell tumor with t(1;17)(p13;p13) and trisomy 5[J]. In Vivo, 2014, 28(5): 949-952.
[23] Nilsson M, Höglund M, Panagopoulos I, et al.Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors[J]. Virchows Arch, 2002, 441(5): 475-480.
[24] Ho J, Peters T, Dickson BC, et al.Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors[J]. Genes Chromosomes Cancer, 2020, 59(2): 96-105.
[25] Tsuda Y, Hirata M, Katayama K, et al.Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations[J]. Int J Cancer, 2019, 145(12): 3276-3284.
[26] Mejbel H, Siegal GP, Wei S.Intramuscular tenosynovial giant cell tumor harboring a Novel CSF1-CD96 fusion transcript[J]. Int J Surg Pathol, 2022, 30(3): 335-338.
[27] Fähnrich A, Gasimova Z, Maluje Y, et al.Case report: tenosynovial giant cell tumor[J]. Front Oncol, 2024, 14: 1445427.
[28] Woo HH, Baker T, Laszlo C, et al.Nucleolin mediates microRNA-directed CSF-1 mRNA deadenylation but increases translation of CSF-1 mRNA[J]. Mol Cell Proteomics, 2013, 12(6): 1661-1677.
[29] Liyasova MS, Ma K, Lipkowitz S.Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment[J]. Clin Cancer Res, 2015, 21(8): 1789-1794.
[30] Assi T, Moussa T, Ngo C, et al.Therapeutic advances in Tenosynovial giant cell tumor: targeting the CSF1/CSF1R axis[J]. Cancer Treat Rev, 2025, 134: 102904.
[31] Györi DS, Mócsai A.Osteoclast signal transduction during bone metastasis formation[J]. Front Cell Dev Biol, 2020, 8: 507.
[32] Lu S, Cao C, Zhang W, et al.Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling[J]. Sci China Life Sci, 2025, 68(3): 593-609.
[33] 王丹丹. 颞下颌关节弥漫型腱鞘巨细胞瘤的临床病理及发病机制研究[D]. 北京: 北京大学医学部, 2021: 38-43.
Wang DD.The clinico-pathological and pathogenic study on diffuse tenosynovial giant cell tumor of temporomandibular joint[D]. Beijing: Peking Univ Health Sci Cent, 2021: 38-43.
[34] van IJzendoorn DGP, Matusiak M, Charville GW, et al. Interactions in CSF1-driven tenosynovial giant cell tumors[J]. Clin Cancer Res, 2022, 28(22): 4934-4946.
[35] Yoshida W, Uzuki M, Kurose A, et al.Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis[J]. Hum Pathol, 2003, 34(1): 65-73.
[36] Zhang C, Liu J, Xu D, et al.Gain-of-function mutant p53 in cancer progression and therapy[J]. J Mol Cell Biol, 2020, 12(9): 674-687.
[37] Elkhamsy FAA, Aboelkomsan EA, Sallam MK, et al.Cytoplasmic PPARγ significantly correlates with p53 immunohistochemical expression and tumor size in localized tenosynovial giant cell tumor[J]. Cureus, 2024, 16(5): e60377.
[38] Fiocco U, Sfriso P, Lunardi F, et al.Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis[J]. Autoimmun Rev, 2010, 9(11): 780-784.
[39] O'Keefe RJ, Rosier RN, Teot LA, et al. Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction[J]. Iowa Orthop J, 1998, 18: 26-34.
[40] Achkova D, Maher J.Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer[J]. Biochem Soc Trans, 2016, 44(2): 333-341.
[41] Xie Y, Chen C, Wu F, et al.Single-cell analysis clarifies pathological heterogeneity in tenosynovial giant cell tumor and identifies biomarkers for predicting disease recurrence[J]. Adv Sci (Weinh), 2025, 12(26): e2415835.
[42] Taylor R, Kashima TG, Knowles H, et al.Osteoclast formation and function in pigmented villonodular synovitis[J]. J Pathol, 2011, 225(1): 151-156.

腱鞘巨细胞瘤的发病机制研究进展

Research progress in the pathogenesis of tenosynovial giant cell tumor

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	陈云亮, 满城, 李晓宇, 伍靖, 魏柳琼, 李文龙. 创伤性颞下颌关节强直与异位骨化发病机制相似性的实验研究[J]. 中国口腔颌面外科杂志, 2023, 21(5): 461-466.
[2]	努尔曼古丽·牙森, 多力昆·吾甫尔, 白尔娜·吾守尔, 闫广鹏. 血清IL-6、IL-17、TNF-α和IFN-γ水平与60例口腔鳞癌患者临床特征关系探讨[J]. 中国口腔颌面外科杂志, 2022, 20(2): 141-145.
[3]	喻康, 沈意涵, 蒋彩玲, 王凤, 吴轶群. 少汗型外胚叶发育不良中EDA基因新突变位点的鉴定[J]. 中国口腔颌面外科杂志, 2021, 19(5): 429-433.
[4]	陈培倩, 陶晓峰, 张春叶, 朱凌. 23例颞下颌关节弥漫性腱鞘巨细胞瘤的CT和MRI特征分析[J]. 中国口腔颌面外科杂志, 2019, 17(4): 359-363.
[5]	李晓, 房兵. 进行性半侧颜面萎缩的病因与发病机制研究进展[J]. 中国口腔颌面外科杂志, 2017, 15(1): 90-93.
[6]	陈嘉珮, 牛振民, 乌丹旦, 杨育生, 黄薇, 陈振琦. 中国人群非综合征性唇腭裂患者IRF6基因突变检测[J]. 中国口腔颌面外科杂志, 2014, 12(4): 333-336.
[7]	金龙, 杨宏宇, 杨辉俊, 沈时岳, 王锋, 谢舒乐, 张珊珊. 颞下窝-颅底弥漫性腱鞘巨细胞瘤1例报告及文献复习[J]. 中国口腔颌面外科杂志, 2014, 12(2): 184-188.
[8]	梁冰;徐辉. 炎症反应在术后认知功能障碍发病机制中的研究进展 [J]. 中国口腔颌面外科杂志, 2013, 11(5): 429-432.